Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07008846 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

Name: Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis — clinical trial record (NCT07008846)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Started2025-05-10

View on ClinicalTrials.gov ↗

Record status

This record was last updated June 6, 2025 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

25 trials monitored

See all monitored trials

Rheumatoid Arthritis

612 trials monitored

See 11 trials at risk

The aim of this study is to assess the efficacy of upadacitinib, methotrexate combination therapy in comparison to tofacitinib, methotrexate combination therapy in moderate to severe RA patients. This study will guide us to treat RA patients with inadequate response to methotrexate more effectively

Trial Details

NCT Number	NCT07008846
Lead Sponsor	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions	Moderate to Severe Rheumatoid Arthritis
Enrollment	96 participants
Start Date	2025-05-10
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-06